Marie Borggren (Former)
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
- Contribution to journal › Scientific review
-
Mark
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
- Contribution to journal › Scientific review
- 2016
-
Mark
Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark
- Contribution to journal › Article
- 2015
-
Mark
The Evolution of HIV-1 Interactions with Coreceptors and Mannose C-Type Lectin Receptors.
- Contribution to journal › Article
- 2013
-
Mark
R5 HIV-1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children.
- Contribution to journal › Article
- 2012
-
Mark
Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011
- Contribution to journal › Article
-
Mark
Intrahost evolution of HIV-1 phenotypes
- Thesis › Doctoral thesis (compilation)
- 2011
-
Mark
Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge.
- Contribution to journal › Article
-
Mark
Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.
- Contribution to journal › Article
- 2010
-
Mark
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference
- Contribution to journal › Scientific review
